A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator?s Choice of Adjuvant Chemotherapy in Participants with Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression (2138-CL-0102)